NCT04291092 is a Phase 2 clinical trial of Immunotherapy in NSCLC Stage IV, sponsored by Zhejiang Cancer Hospital.

Who is sponsoring NCT04291092?

NCT04291092 is sponsored by Zhejiang Cancer Hospital.

What drugs are being tested in NCT04291092?

Interventions in NCT04291092: Immunotherapy, WBRT, Chemotherapy.

What condition does NCT04291092 study?

NCT04291092 studies NSCLC Stage IV, Brain Metastases, Immunotherapy.

Is NCT04291092 still recruiting?

NCT04291092 is currently status unknown. Last updated 10 September 2021.

Last reviewed 2021-09-10 · How we verify

NCT04291092

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Camrelizumab Combined With Local Treatment in NSCLC Patients With BM

Status unknown Phase 2 Last updated 10 September 2021

What this trial tests

Phase 2 trial testing Immunotherapy in NSCLC Stage IV in 63 participants. Status unknown.

Timeline

1 January 2020

Primary endpoint
30 June 2022

30 June 2023

Quick facts

Lead sponsor	Zhejiang Cancer Hospital
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	63
Start date	1 January 2020
Primary completion	30 June 2022
Estimated completion	30 June 2023
Sites	1 location across China

Drugs / interventions tested

Immunotherapy — full drug profile →
WBRT — full drug profile →
Chemotherapy (chemotherapy) — full drug profile →

Conditions studied

NSCLC Stage IV — all drugs for NSCLC Stage IV →
Brain Metastases — all drugs for Brain Metastases →
Immunotherapy — all drugs for Immunotherapy →

Sponsor

Zhejiang Cancer Hospital

Who can join

18 and older, any sex, with NSCLC Stage IV or Brain Metastases. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To evaluate the efficacy and safety of Camrelizumab Combined with Chemotherapy and Local Treatment in non-small cell lung cancer with brain metastases.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Radiotherapy combined with immunotherapy: the dawn of cancer treatment.
Zhang Z, Liu X, Chen D, Yu J. · · 2022 · cited 463× · PMID 35906199 · DOI 10.1038/s41392-022-01102-y
Modern Radiation Therapy for the Management of Brain Metastases From Non-Small Cell Lung Cancer: Current Approaches and Future Directions.
Mantovani C, Gastino A, Cerrato M, Badellino S, et al · · 2021 · cited 37× · PMID 34796118 · DOI 10.3389/fonc.2021.772789
The Role of Microglia in Brain Metastases: Mechanisms and Strategies.
Feng Y, Hu X, Zhang Y, Wang Y. · · 2024 · cited 27× · PMID 37307835 · DOI 10.14336/ad.2023.0514
Brain radiotherapy combined with camrelizumab and platinum-doublet chemotherapy for previously untreated advanced non-small-cell lung cancer with brain metastases (C-Brain): a multicentre, single-arm, phase 2 trial.
Xu Y, Chen K, Xu Y, Li H, et al · · 2025 · cited 16× · PMID 39756446 · DOI 10.1016/s1470-2045(24)00643-0
Exploring the Molecular Tumor Microenvironment and Translational Biomarkers in Brain Metastases of Non-Small-Cell Lung Cancer.
Wen J, Yu JZ, Liu C, Ould Ismail AAO, et al · · 2024 · cited 13× · PMID 38396722 · DOI 10.3390/ijms25042044
Modern Stereotactic Radiotherapy for Brain Metastases from Lung Cancer: Current Trends and Future Perspectives Based on Integrated Translational Approaches.
Levis M, Gastino A, De Giorgi G, Mantovani C, et al · · 2023 · cited 11× · PMID 37760591 · DOI 10.3390/cancers15184622
Radiotherapy combined with PD-1/PD-L1 inhibitors in NSCLC brain metastases treatment: The mechanisms, advances, opportunities, and challenges.
Chen ZY, Duan XT, Qiao SM, Zhu XX. · · 2023 · cited 10× · PMID 35986515 · DOI 10.1002/cam4.5016
Molecular and Clinical Premises for the Combination Therapy Consisting of Radiochemotherapy and Immunotherapy in Non-Small Cell Lung Cancer Patients.
Frąk M, Krawczyk P, Kalinka E, Milanowski J. · · 2021 · cited 9× · PMID 33799560 · DOI 10.3390/cancers13061222

Verify or expand the search:

Other trials of Immunotherapy

Trials testing the same drug.

NCT07293247 — A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After · Phase 2 · not yet recruiting
NCT07259473 — Factors Influencing Immunotherapy Response in dMMR/MSI-H Gastric/Gastroesophageal Junction Adenocarcinoma · Phase 2 · not yet recruiting
NCT07258147 — Safety and Efficacy of Radiotherapy Combined With Immunochemotherapy in Pre-treated SCLC Patients With Liver Metastases · Phase 2 · not yet recruiting
NCT07297030 — SIB-RT Combined With CAPOX and PD-1 for High-Risk Rectal Cancer · Phase 2 · not yet recruiting
NCT07231575 — Neoadjuvant SBRT and Tislelizumab (Immunotherapy) Plus Anlotinib for Resectable EGFR Wild-type NSCLC · Phase 2 · not yet recruiting

Other recruiting trials for NSCLC Stage IV

Currently open trials in the same condition.

NCT07279402 — TRIMPACT: Real-World First-Line Atezolizumab Use in Stage IV NSCLC With PD-L1 ≥50% · recruiting
NCT06401824 — Sacituzumab Govitecan and Bevacizumab for NSCLC Brain Metastases · Phase 2 · recruiting
NCT06532149 — ERectile Dysfunctions, gOnadotoxicity and Sexual Health Assessment in Men With Lung Cancer · recruiting
NCT06313541 — Treatment Response Adapted Hybrid Radiotherapy in Metastatic Non-small Cell Lung Cancer Receiving First-line Immunothera · Phase 2 · recruiting
NCT06788366 — AI-HOPE Lung Cancer: Building a Predictive Tool for Metastatic Lung Cancer · recruiting

Other Zhejiang Cancer Hospital trials

Trials by the same sponsor.

NCT07343479 — Sacituzumab Tirumotecan Plus Third-Generation TKI With/Without Radiotherapy for EGFR-Mutant NSCLC Brain Metastases · Phase 2 · not yet recruiting
NCT07441720 — Safety and Efficacy of Umbilical Cord Blood Therapy for Cancer Therapy-Induced Thrombocytopenia (CTIT) · Phase 2 · recruiting
NCT07416890 — Thiotepa in Combination With Pirtobrutinib (a BTK Inhibitor) and Sintilimab (a PD-1 Inhibitor) for Frail or Relapsed/Ref · Phase 2 · recruiting
NCT07326150 — Construction of a Predictive Model for the Efficacy of Chemoprevention Combined With Targeted Therapy in Pancreatic Canc · active not recruiting
NCT07330544 — A Phase II Clinical Study Evaluating Entinostat With or Without Anlotinib + Fulvestrant for the Treatment of Hormone Rec · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04291092 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Zhejiang Cancer Hospital
Last refreshed: 10 September 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04291092.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing